<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8445">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833781</url>
  </required_header>
  <id_info>
    <org_study_id>2008p001577</org_study_id>
    <secondary_id>R01AI066992-04</secondary_id>
    <secondary_id>DAIDS-ES ID 10731</secondary_id>
    <nct_id>NCT00833781</nct_id>
  </id_info>
  <brief_title>A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects</brief_title>
  <acronym>PARC002</acronym>
  <official_title>A Pilot, Double-blind, Placebo-controlled, Randomized Clinical Trial of mRNA-transfected Autologous Dendritic Cells in Subjects With Well-controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out whether an experimental autologous dendritic cell
      vaccine is safe, well tolerated, and whether it can strengthen the immune system's response
      to HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized trial to evaluate whether mRNA-transfected dendritic cell vaccination
      is safe and immunogenic in HIV-infected participants who are on antiretroviral therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of the DC Vaccine (as Measured by Frequency of Adverse Events)</measure>
    <time_frame>After vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with grade 3 or 4 adverse events related to vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 14 in ELISPOT Response to Gag and Nef</measure>
    <time_frame>Baseline and 14 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity was measure by interferon gamma enzyme-linked immunospot (ELISPOT) assay. The number of spot forming cells per million PBMC was determined at each time point. The fold ratio represents week 14 value divided by value at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T Cell Proliferation</measure>
    <time_frame>Baseline to week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL2 and IFN Gamma Production</measure>
    <time_frame>Baseline to week 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>mRNA-transfected dendritic cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm/group received mRNA-transfected autologous dendritic cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dendritic cells without mRNA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm/group received autologous dendritic cells with no mRNA transfection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-transfected autologous dendritic cells</intervention_name>
    <description>Injections will be administered intradermally at weeks 0, 2, 6 and 10.</description>
    <arm_group_label>mRNA-transfected dendritic cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous dendritic cells with no mRNA transfection</intervention_name>
    <description>Injections will be administered intradermally at weeks 0, 2, 6 and 10.</description>
    <arm_group_label>Dendritic cells without mRNA</arm_group_label>
    <other_name>Autologous dendritic cells not transfected with mRNA.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 positive

          -  CD4+ T Cell count &gt;200

          -  Undetectable HIV viral load for 6 months prior to screening

          -  On antiretroviral treatment for 12 months prior to screening

        Exclusion Criteria:

          -  Hepatitis C positive

          -  Detectable HIV viral load within 6 months prior to study entry

          -  Females who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Gandhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Disease Unit; Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gandhi RT, Kwon DS, Macklin EA, Shopis JR, McLean AP, McBrine N, Flynn T, Peter L, Sbrolla A, Kaufmann DE, Porichis F, Walker BD, Bhardwaj N, Barouch DH, Kavanagh DG. Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):246-53. doi: 10.1097/QAI.0000000000000852.</citation>
    <PMID>26379068</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 3, 2016</lastchanged_date>
  <firstreceived_date>January 29, 2009</firstreceived_date>
  <firstreceived_results_date>October 15, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Rajesh T. Gandhi, MD</investigator_full_name>
    <investigator_title>Director of Education</investigator_title>
  </responsible_party>
  <keyword>HIV vaccine</keyword>
  <keyword>Dendritic cells</keyword>
  <keyword>treatment experienced</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>mRNA-transfected Autologous Dendritic Cell Vaccine.</title>
          <description>mRNA-transfected autologous dendritic cells: Injections will be administered intradermally at weeks 0, 2, 6 and 10.</description>
        </group>
        <group group_id="P2">
          <title>Autologous Dendritic Cells Without Transfected mRNA.</title>
          <description>Dendritic cell vaccine without transfected mRNA.
Autologous dendritic cells not transfected with mRNA.: Injections will be administered intradermally at weeks 0, 2, 6 and 10.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>mRNA-transfected Autologous Dendritic Cell Vaccine.</title>
          <description>mRNA-transfected autologous dendritic cells: Injections will be administered intradermally at weeks 0, 2, 6 and 10.</description>
        </group>
        <group group_id="B2">
          <title>Autologous Dendritic Cells Without Transfected mRNA.</title>
          <description>Dendritic cell vaccine without transfected mRNA.
Autologous dendritic cells not transfected with mRNA.: Injections will be administered intradermally at weeks 0, 2, 6 and 10.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44" lower_limit="33" upper_limit="55"/>
                <measurement group_id="B2" value="49" lower_limit="42" upper_limit="52"/>
                <measurement group_id="B3" value="46.7" lower_limit="33" upper_limit="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of the DC Vaccine (as Measured by Frequency of Adverse Events)</title>
        <description>Number of participants with grade 3 or 4 adverse events related to vaccination</description>
        <time_frame>After vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>mRNA-transfected Autologous Dendritic Cells</title>
            <description>Injections were administered intradermally at weeks 0, 2, 6 and 10.</description>
          </group>
          <group group_id="O2">
            <title>Dendritic Cell Vaccine Without Transfected mRNA.</title>
            <description>Injections were administered intradermally at weeks 0, 2, 6 and 10.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Safety of the DC Vaccine (as Measured by Frequency of Adverse Events)</title>
            <description>Number of participants with grade 3 or 4 adverse events related to vaccination</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T Cell Proliferation</title>
        <time_frame>Baseline to week 14</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>mRNA-transfected Autologous Dendritic Cells</title>
            <description>Injections were administered intradermally at weeks 0, 2, 6 and 10.</description>
          </group>
          <group group_id="O2">
            <title>Dendritic Cell Vaccine Without Transfected mRNA.</title>
            <description>Injections were administered intradermally at weeks 0, 2, 6 and 10.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>T Cell Proliferation</title>
            <units>fold change</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>CD4 Gag proliferative response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.465" lower_limit="1.167" upper_limit="5.208"/>
                  <measurement group_id="O2" value="0.717" lower_limit="0.253" upper_limit="2.033"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CD4 Nef Proliferative response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.292" lower_limit="1.044" upper_limit="5.035"/>
                  <measurement group_id="O2" value="0.363" lower_limit="0.12" upper_limit="1.102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 14 in ELISPOT Response to Gag and Nef</title>
        <description>Immunogenicity was measure by interferon gamma enzyme-linked immunospot (ELISPOT) assay. The number of spot forming cells per million PBMC was determined at each time point. The fold ratio represents week 14 value divided by value at baseline.</description>
        <time_frame>Baseline and 14 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>mRNA-transfected Autologous Dendritic Cells</title>
            <description>Injections were administered intradermally at weeks 0, 2, 6 and 10.</description>
          </group>
          <group group_id="O2">
            <title>Dendritic Cell Vaccine Without Transfected mRNA.</title>
            <description>Injections were administered intradermally at weeks 0, 2, 6 and 10.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Week 14 in ELISPOT Response to Gag and Nef</title>
            <description>Immunogenicity was measure by interferon gamma enzyme-linked immunospot (ELISPOT) assay. The number of spot forming cells per million PBMC was determined at each time point. The fold ratio represents week 14 value divided by value at baseline.</description>
            <units>fold ratio</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Gag ELISPOT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.06" lower_limit="0.893" upper_limit="1.259"/>
                  <measurement group_id="O2" value="1.058" lower_limit="0.836" upper_limit="1.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nef ELISPOT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.15" lower_limit="0.979" upper_limit="1.351"/>
                  <measurement group_id="O2" value="1.021" lower_limit="0.813" upper_limit="1.281"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL2 and IFN Gamma Production</title>
        <time_frame>Baseline to week 14</time_frame>
        <population>Results from these assays were too variable to be interpretable.</population>
        <group_list>
          <group group_id="O1">
            <title>mRNA-transfected Autologous Dendritic Cells</title>
            <description>Injections were administered intradermally at weeks 0, 2, 6 and 10.</description>
          </group>
          <group group_id="O2">
            <title>Dendritic Cell Vaccine Without Transfected mRNA.</title>
            <description>Injections were administered intradermally at weeks 0, 2, 6 and 10.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>IL2 and IFN Gamma Production</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>mRNA Transfected DCs</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial size is small, precluding detection of small effect sizes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Rajesh Gandhi</name_or_title>
      <organization>Mass General Hospital</organization>
      <phone>617-724-9690</phone>
      <email>rgandhi@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
